About Eledon
Eledon is a publicly listed company based in Irvine (United States) founded in 2004. Therapeutics for transplantation in autoimmune and neurodegenerative diseases are developed. Eledon has raised $1.89 million across 7 funding rounds from investors including Orbimed and BVF Partners. The company has 31 employees. Eledon has completed 1 acquisition, including Anelixis Therapeutics. Eledon offers products and services including Tegoprubart. Its focus areas include Life Sciences, Neurology, Drugs and Diversified. Its legal entity is Eledon Pharmaceuticals, Inc. Its competitors include Biogen, CareDx and Neurocrine; 3 of its 3 listed competitors have raised funding.
Company details
Eledon was founded in 2004 and is based in Irvine, United States. Operations focus on the biotechnology sector, where solutions for organ and cellular transplantation are provided to address autoimmune and neurodegenerative diseases. The CD40L pathway is targeted through antibodies, with AT-1501 developed for pro-inflammatory responses in autoimmune conditions, transplant rejection, and neuroinflammation. AT-2001 is also advanced for autoimmune indications.
- Headquarters Irvine, United States
- Employees 31
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website eledon.com
- Social LinkedIn X
- Legal Name Eledon Pharmaceuticals, Inc.
- Net Profit-$45.62 M (USD)-26.07as on Dec 31, 2025
- EBITDA-$83.25 M (USD)-18.56as on Dec 31, 2025
- Total Equity Funding$1.89M (USD)
in 7 rounds
- Latest Funding Round$50M (USD), Post-IPO
May 2024
- InvestorsOrbimed
& 1 more
- Employee Count31
- Investments & Acquisitions
Products & Services of Eledon
Eledon offers a comprehensive portfolio of products and services, including Tegoprubart.
Antibody designed to prevent immune rejection in organ transplants.
Funding Insights of Eledon
Eledon has successfully raised a total of $1.89M across 7 strategic funding rounds. The most recent funding activity was a Post-IPO round of $50 million completed in May 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $1.89M
- Total Rounds 7
- Last Round Post-IPO — $50M
- First Round $1.89M
(Sep 2011)
- Investors Count 2
All 7 funding rounds of Eledon with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| May 2024 | $50M | Post-IPO | – | – | – |
| May 2023 | $35M | Post-IPO | – | – | – |
| Sep 2020 | $108.14M | Post-IPO | – | – | |
| Jan 2020 | $862,278 | Post-IPO | – | – | – |
| May 2019 | $862,278 | Post-IPO | – | – | – |
| May 2017 | $4M | Post-IPO | – | – | |
| Sep 2011 | $1.89M | Seed | – | – | – |
2 investors in total: 2 institutional.
Investors in Eledon
Eledon has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include Orbimed and BVF Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
US private equity investments are managed by BVF Partners. | bvflp.com | San Francisco, United States | ||
Investments are made by OrbiMed in global healthcare innovations across biopharmaceuticals and related fields. | 1989 | orbimed.com | New York, United States |
Investor details for Eledon
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Eledon
23 people are tracked at Eledon (15 in leadership, 4 in board & advisors, 4 in team); the tracked headcount is 31.
| Name | Role | Group |
|---|---|---|
Elizabeth Thomas | Director Biostatistics | Leadership |
John Herberger | Vice President Technical Operations | Leadership |
David Hovland | Chief Regulatory Officer | Leadership |
Steven Perrin | President And Chief Scientific Officer | Leadership |
Bryan Smith | General Counsel, Chief Compliance Officer, & Corporate Secretary | Leadership |
Paul Little | Chief Financial Officer | Leadership |
David-Alexandre C. Gros | Chief Executive Officer & Director | Leadership |
Sepideh Habibi | Vp, Head Of Safety And Pharmacovigilance | Leadership |
Jamie Hoang | Senior Director Corporate Controller | Leadership |
Eliezer Katz | Chief Medical Officer | Leadership |
Carmen Mak | VP, Biometrics | Leadership |
Shana Burns | Associate Director, Clinical Data Management | Leadership |
Marina Escudero | Vice President, Clinical Operations | Leadership |
Mandy Williams | Associate Director, Clinical Site Liaison | Leadership |
Brooke Hegarty | Director Clinical Operations | Leadership |
Jan Hillson | Director | Board & advisors |
Keith A. Katkin | Chairman | Board & advisors |
John S. McBride | Director | Board & advisors |
June Lee | Director | Board & advisors |
Alexandra Miller Fiset | Senior Clinical Project Manager | Team |
3 more people are available in the full profile.
Complete people profiles for Eledon
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Eledon
Eledon is a publicly listed company on the NASDAQ with ticker symbol ELDN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date22 Sep 2014
- Listed onNASDAQ: ELDN
- Listed entityEledon Pharmaceuticals, Inc.
- Exchange sectorHealth technology
- ISINUS28617K1016
- Share price$2.34 (-4.1% on the day) · 2026-10-13
- Market capitalisation$190.2M
- EPS (diluted, trailing year)$-0.99
- Volume (last session)1,167,731
Financials of Eledon
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | -$45.6M | -$83.2M | |
| 2024 | -$36.2M | -$70.2M | |
| 2023 | -$116.5M | -$42.6M | |
| 2022 | -$88.0M | -$39.4M | |
| 2021 | -$34.5M | -$36.7M |
Detailed financial statements for Eledon
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Eledon
Eledon has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Anelixis Therapeutics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
CD40 and SOD1 targeting drugs are developed for ALS treatment. | anelixistherapeutics.com | Cambridge, United States | 2013 | Sep 2020 | •••• |
Complete acquisition details for Eledon
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Eledon
5 dated milestones of Eledon across 20 years, from founding to its latest funding, stage changes and deals.
- Founded Eledon is founded.
- Funding First funding round of $1.9M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Anelixis Therapeutics.
- Funding Latest funding round, Post-IPO, of $50.0M.
Competitors of Eledon
Eledon has 3 listed competitors in our database, 3 of them funded. They include Biogen, CareDx and Neurocrine.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| biogen.com | 1978 | Cambridge, United States | $80M | 1 | Therapies for neurodegenerative and immunology disorders are developed. | |
| caredx.com | 1998 | Brisbane, United States | $138.21M | 645 | Medical solutions for transplant patients are developed and provided. | |
| neurocrine.com | 1992 | San Diego, United States | $10M | 1,400 | Developer of small molecule therapeutics for endocrine and CNS disorders |
Detailed competitors of Eledon
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Eledon
The website of Eledon (eledon.com) receives about 7.5K visits a month.
- Monthly visits7.5K
▼ 35.4% vs previous month
Top companies in Transplant Medicine
3 companies that operate in the same segment as Eledon (Transplant Medicine) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medical solutions for transplant patients are developed and provided. | 1998 | Brisbane, California, United States | USD 138.21 M | USD 379.81 M | 650 | |
Developer of organ transplantation technology | 1998 | Andover, Massachusetts, United States | USD 265.55 M | USD 605.49 M | 728 | |
Human tissue-based products are developed for vascular disease applications. | 2004 | Morrisville, United States | USD 424.76 M | USD 2.04 M | 220 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Eledon
Complete news archive for Eledon
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Eledon
Eledon was founded in 2004 and raised its 1st funding round 7 years after it was founded.
Eledon is headquartered in Irvine, United States. It is registered at Irvine, California, United States.
Eledon is a funded company, having raised a total of $1.89M across 7 funding rounds to date. The company's 1st funding round was a Seed of $1.89M, raised on Sep 2011.
Eledon has 31 employees.
Eledon was founded in 2004 and is based in Irvine, United States. Operations focus on the biotechnology sector, where solutions for organ and cellular transplantation are provided to address autoimmune and neurodegenerative diseases. The CD40L pathway is targeted through antibodies, with AT-1501 developed for pro-inflammatory responses in autoimmune conditions, transplant rejection, and neuroinflammation. AT-2001 is also advanced for autoimmune indications.
Eledon's top competitors include CareDx, Neurocrine and Biogen.
Eledon offers Tegoprubart.
Yes, Eledon is publicly traded on NASDAQ under the ticker symbol ELDN.
Eledon has made 1 acquisition, including Anelixis Therapeutics.
Eledon has 2 investors. Key investors include Orbimed, and BVF Partners.
Eledon operates through Eledon Pharmaceuticals, Inc..